The POSEIDON Trial With Tejas Patil
from Lung Cancer Considered Hosted by IASLC
Dr. Narjust Florez discusses the POSEIDON trial with guest Dr. Tejas Patil, assistant professor at Thoracic Oncology Research Initiative, University of Colorado Cancer Center. This Phase III study led to the recent FDA approval of Tremelimumab in combination with Durvalumab and chemotherapy as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC).
Embed this episode
No transcript yet.
Similar podcasts
Frequently asked questions
How long is this episode of Lung Cancer Considered?
This episode is 33 minutes long.
When was this Lung Cancer Considered episode published?
This episode was published on November 28, 2022.
Can I download this Lung Cancer Considered episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.